Join us for an episode featuring a distinguished panel of experts as they dive into pricing and deal valuation dynamics for multi-indication products. The conversation explores the key questions commercialization partners, acquirers, and capital providers ask when evaluating both multi-indication and platform products for deal valuation.

Hear firsthand insights from CEOs, business development executives, market access leaders, country managers, and royalty investors representing leading companies such as Alexion, DRI Capital, Genentech, Genzyme, GSK, and Pfizer.